Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(16):1184-1185; doi:10.1093/jnci/94.16.1184
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Varricchio, C. G.
Right arrow Articles by Sloan, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varricchio, C. G.
Right arrow Articles by Sloan, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 16, 1184-1185, August 21, 2002
© 2002 Oxford University Press

EDITORIAL

The Need for and Characteristics of Randomized, Phase III Trials to Evaluate Symptom Management in Patients With Cancer

Claudette G. Varricchio, Jeff A. Sloan

Affiliations of authors: C. G. Varricchio, Office of Extramural Programs, National Institute of Nursing Research, Bethesda, MD; Jeff A. Sloan, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

Correspondence to: Claudette G. Varricchio, D.S.N., R.N., F.A.A.N., National Institute of Nursing Research, National Institutes of Health, One Democracy Plaza, 6701 Democracy Blvd., Rm. 710, Bethesda, MD 20892–4870 (e-mail varriccc@mail.nih.gov).

The first 10% of the full text of this article appears below.

The paradigm of cancer research has evolved from goals restricted to tumor response and survival end points to include goals relating to optimal control of cancer-related symptoms. The initial declaration of the War on Cancer set the target goal at the total eradication of cancer. However, the gradual change in cancer being increasingly treated as a chronic rather than an acute condition has warranted a shift toward examining progress in the management of disease and treatment-related symptoms in phase III clinical trials.

The challenge inherent in studying . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
D. L. Hershman
Getting a Grip on Aromatase Inhibitor-Associated Arthralgias
J. Clin. Oncol., July 1, 2008; 26(19): 3120 - 3121.
[Full Text] [PDF]

Home page
 JCOHome page
D. W. Bruner
Should Patient-Reported Outcomes Be Mandatory for Toxicity Reporting in Cancer Clinical Trials?
J. Clin. Oncol., December 1, 2007; 25(34): 5345 - 5347.
[Full Text] [PDF]

Home page
 JCOHome page
D. Watkins Bruner, C. J. Bryan, N. Aaronson, C. C. Blackmore, M. Brundage, D. Cella, P. A. Ganz, C. Gotay, P. S. Hinds, A. B. Kornblith, et al.
Issues and Challenges With Integrating Patient-Reported Outcomes in Clinical Trials Supported by the National Cancer Institute Sponsored Clinical Trials Networks
J. Clin. Oncol., November 10, 2007; 25(32): 5051 - 5057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Trotti, A. D. Colevas, A. Setser, and E. Basch
Patient-Reported Outcomes and the Evolution of Adverse Event Reporting in Oncology
J. Clin. Oncol., November 10, 2007; 25(32): 5121 - 5127.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. F. Vansteenkiste and A. B. Colowick
RESPONSE: Re: Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy
J Natl Cancer Inst, May 21, 2003; 95(10): 762 - 763.
[Full Text] [PDF]